Article
Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.
Gynecologic oncology - 1 Jul 2023
Rios-Doria Eric, Momeni-Boroujeni Amir, Friedman Claire F, Selenica Pier, Zhou Qin, Wu Michelle, Marra Antonio, Leitao Mario M, Iasonos Alexia, Alektiar Kaled M, Sonoda Yukio, Makker Vicky, Jewell Elizabeth, Liu Ying, Chi Dennis, Zamarin Dimitry, Abu-Rustum Nadeem R, Aghajanian Carol, Mueller Jennifer J, Ellenson Lora H, Weigelt Britta
Abstract excerpt
PURPOSE: Using next generation sequencing (NGS), The Cancer Genome Atlas (TCGA) found that endometrial carcinomas (ECs) fall under one of four molecular subtypes, and a POLE mutation status, mismatch repair (MMR) and p53 immunohistochemistry (IHC)-based surrogate has been developed. We sought to retrospectively classify and characterize a large series of unselected ECs that were prospectively subjected to...
Topics
- Female
- Humans
- Tumor Suppressor Protein p53
- Immunohistochemistry
- Retrospective Studies
- Endometrial Neoplasms
- Prognosis
- Mutation